



Securities Code: 4523

FY 2014 (Ending March 31, 2015)  
Third Quarter Financial Results

# Reference Data

January 30, 2015

Eisai Co., Ltd.

For Inquiries:

Public Relations: TEL +81-(0)3-3817-5120

Investor Relations: TEL +81-(0)3-3817-3016

<http://www.eisai.com/>

## **Forward-Looking Statements and Risk Factors**

Materials and information provided in this financial disclosure may contain "forward-looking statements" based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations.

Risks that may cause significant fluctuations in the consolidated results of the Eisai Group or have a material effect on investment decisions are described below. These are risk factors that have been identified and assessed as of the disclosure date of the Financial Report.

Risk factors associated with our business include, but are not limited to, challenges arising in overseas operations, uncertainties in new drug development, as well as risks related to strategic alliances with partner companies, medical cost-containment measures, generic drug products, intellectual property, possible occurrence of side effects, laws and regulations, litigation, closure or shutdown of production plants, safety and quality of raw materials, outsourcing, environmental issues, IT security and information management, financial market conditions and currency movement, internal control systems, and disasters.

This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

# Contents

<b>1. Consolidated Statement of Income</b>	-----	<b>1</b>
<b>2. Capital Expenditures, Depreciation and Amortization</b>	-----	<b>2</b>
<b>3. Segment Information</b>	-----	<b>2</b>
<b>4. Financial Results by Reporting Segment</b>	-----	<b>3</b>
<b>5. Revenue from Major Products</b>	-----	<b>7</b>
<b>6. Sales Forecasts by Reporting Segment</b>	-----	<b>9</b>
<b>7. Consolidated Statement of Comprehensive Income</b>	-----	<b>10</b>
<b>8. Consolidated Statement of Cash Flows</b>	-----	<b>11</b>
<b>9. Consolidated Statement of Financial Position</b>	-----	<b>12</b>
<b>10. Changes in Quarterly Results</b>	-----	<b>14</b>
	-----	<b>17</b>

## Currency Exchange Rates

	US (JPY/USD)	EU (JPY/EUR)	UK (JPY/GBP)	China (JPY/RMB)
Quarterly Average Rate	99.38	132.22	155.88	16.24
Quarter End Rate	105.39	145.05	173.76	17.36
Yearly Average	100.23	134.36	159.44	16.41
Year End Rate	102.92	141.65	171.31	16.59
Quarterly Average Rate	106.87	140.30	175.57	17.29



## 2. Capital Expenditures, Depreciation and Amortization

(billions of yen)

	FY 2014				Revised	Previous
Capital expenditure	22.5	31.2	11.0	(11.4)	<u>20.0</u>	27.5
Property, plant and equipment	5.4	12.3	5.8	0.3	<u>9.5</u>	12.0
Intangible assets	17.0	18.9	5.2	(11.8)	<u>10.5</u>	15.5
Depreciation and amortization	29.9	39.9	28.5	(1.4)	<u>38.5</u>	37.6

## 3. Segment Information

1) Revenue by Reporting Segment 38.34 692.8403 Tm(Capital E 7.6)Tj/TT4 aT9(apital E 7.6



## 2) Americas Pharmaceutical Business (North, Central and South America)

(billions of yen)

	FY 2013		FY 2014	
	Q3	Full year	Q3	YOY (%)
Revenue	106.8	158.9	87.5	82.0 <76.2>
United States	106.3	158.3	86.9	81.7 <76.0>
Segment profit	17.3		11.0	63.6 <59.9>
<b>Americas - revenue from major products</b>				
Antiemetic agent Aloxi	32.2	42.9	36.2	112.5 <104.7>
United States	32.2	42.9	36.2	112.5
[Millions USD]	[324]	[428]	[339]	<104.6>
Anticancer agent Halaven	9.9	13.4	11.9	120.5 <112.3>
United States	9.7	13.1	11.6	119.6
[Millions USD]	[98]	[130]	[109]	<111.2>
Proton-pump inhibitor Aciphex	33.4	37.7	9.4	28.3 <26.3>
[Millions USD]	[336]	[376]	[88]	
Antiepileptic agent Banzel	5.6	7.6	7.3	130.6 <121.5>
United States	5.5	7.5	7.2	131.0
[Millions USD]	[56]	[75]	[68]	<121.8>
Antiobesity agent BELVIQ	1.7	2.5	3.9	235.6 <219.1>
[Millions USD]	[17]	[25]	[37]	
Antiepileptic agent Fycompa	0.0	0.8	0.9	3709.0 <3472.4>
United States		0.7	0.8	
[Millions USD]	( )	[7]	[7]	< >

\* The U.S. is the only country in the Americas where Eisai markets Aciphex and BELVIQ.

\* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

### 3) China Pharmaceutical Business

	FY 2013		FY 2014	
	Q3	Full year	Q3	YOY (%)
Revenue	23.6	31.8	30.0	127.4 <119.6>
Segment profit	5.9		8.3	139.3 <125.4>

#### China - revenue from major products

Peripheral neuropathy treatment		10.5	13.8	13.0	123.8
Methycobal	[Millions RMB]	[645]	[844]	[750]	<116.2>
Liver disease / Allergic disease agents		3.8	5.4	4.9	129.1
Stronger Neo-Minophagen C and Glycyron Tablets	[Millions RMB]	[234]	[331]	[283]	<121.3>
Alzheimer's disease treatment		2.8	3.8	3.4	123.8
Aricept	[Millions RMB]	[170]	[234]	[198]	<116.3>
Proton pump inhibitor		1.6	2.2	2.1	131.0
Pariet	[Millions RMB]	[99]	[135]	[121]	<123.0>

### 4) Asia Pharmaceutical Business (South Korea, Taiwan, Hong Kong, India and ASEAN)

	FY 2013		FY 2014	
	Q3	Full year	Q3	YOY (%)
Revenue	19.8	26.2	22.8	115.3 <107.5>
Segment profit	4.4		5.5	125.1 <113.8>

#### Asia - revenue from major products

Alzheimer's disease treatment		6.1	8.1	6.8	111.4
Aricept					<102.0>
Fully human anti-TNF- monoclonal antibody		5.3	6.8	6.0	114.3
Humira					<104.7>
Proton-pump inhibitor		2.6	3.5	2.7	105.6
Pariet					<100.5>
Peripheral neuropathy treatment		1.7	2.3	2.0	112.0

## 5) EMEA Pharmaceutical Business (Europe, the Middle East, Africa and Oceania)

(billions of yen)

	FY 2013		FY 2014	
	Q3	Full year	Q3	YOY (%)
Revenue	23.8	32.0	28.5	119.8 <112.3>
Segment profit	3.5		4.8	139.2 <130.8>
<b>EMEA - revenue from major products</b>				
Anticancer agent Halaven	6.1	8.5	8.4	137.8 <128.6>
Antiepileptic agent Zonegran	4.9	6.6	6.1	125.6 <117.5>
Antiepileptic agent Zebinix	1.8	2.4	2.4	135.7 <127.4>
Antiepileptic agent Fycompa	1.0	1.3	1.7	177.3 <164.2>
Antiepileptic agent Inovelon	1.4	1.9	1.6	114.0 <106.6>

\* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

## 6) Consumer Healthcare Business Japan (mainly OTC products)

(billions of yen)

	FY 2013		FY 2014	
	Q3	Year end	Q3	YOY (%)
Revenue	14.5	19.3	13.2	91.2
Segment profit	2.8		1.2	42.1
<b>Consumer Healthcare Business Japan - revenue from major products</b>				
Vitamin B2 preparation, "Chocola BB Plus," etc. Chocola BB Group	9.2	12.0	8.3	89.6



## 5. Revenue from Major Products

### 1) Oncology-Related Products

(billions of yen)

	FY 2013		FY 2014	
	Q3	Full year	Q3	YOY (%)
<b>Total</b>	77.3	100.7	72.6	93.9 <88.2>
<b>Halaven (Anticancer agent)</b>	21.3	28.8	25.8	120.9 <114.2>
Japan	5.0	6.4	4.5	91.5
Americas	9.9	13.4	11.9	120.5 <112.3>
Asia	0.3	0.5	0.8	269.1 <251.3>
EMEA	6.1	8.5	8.4	137.8 <128.6>
<b>Aloxi (Antiemetic agent)</b>	32.2	42.9	36.2	112.5 <104.7>
<b>Treakisym/Symbenda (Anticancer agent)</b>	3.0	3.9	2.8	93.2 <92.6>
<b>Other</b>	20.8	25.1	7.8	37.5 <35.4>

\* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

### 2) Epilepsy Products

(billions of yen)

	FY 2013		FY 2014	
	Q3	Full year	Q3	YOY (%)
<b>Total</b>	17.3	24.1	22.9	131.9 <123.5>
<b>Fycompa (Antiepileptic agent)</b>	1.0	2.1	2.6	261.9 <243.4>
Americas	0.0	0.8	0.9	3,709.0 <3,472.4>
EMEA	1.0	1.3	1.7	177.3 <164.2>
<b>Zonegran (Antiepileptic agent)</b>	6.8	9.1	7.8	114.9 <107.3>
EMEA	4.9	6.6	6.1	125.6 <117.5>
<b>Inovelon/Banzel (Antiepileptic agent)</b>	7.1	9.7	9.2	128.9 <120.2>
Americas	5.6	7.6	7.3	130.6 <121.5>
EMEA	1.4	1.9	1.6	114.0 <106.6>
<b>Zebinix (Antiepileptic agent)</b>	1.8	2.4	2.4	135.7 <127.4>
<b>Other</b>	0.6	0.9	0.8	132.7 <132.7>

\* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

### 3) Pariet/Aciphex (Proton-pump inhibitor)

	(billions of yen)			
	FY 2013		FY 2014	
	Q3	Full year	Q3	YOY (%)
<b>Total</b>	75.0	91.4	43.5	58.1 <56.8>
Japan	36.9	47.3	28.8	78.1
Americas	33.4	37.7	9.4	28.3 <26.3>
China	1.6	2.2	2.1	131.0 <123.0>
Asia	2.6	3.5	2.7	105.6 <100.5>

\* The revenue for Pariet in Japan includes the revenue for triple formulation packs for *Helicobacter pylori* eradication, Rabecure Pack 400/800 and Rabefine Pack.

\* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

### 4) Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)

	(billions of yen)			
	FY 2013		FY 2014	
	Q3	Full year	Q3	YOY (%)
<b>Total</b>	66.4	82.7	49.4	74.5 <73.1>
Japan	52.3	65.1	37.0	70.8
China	2.8	3.8	3.4	123.8 <116.3>
Asia	6.1	8.1	6.8	111.4 <102.0>

\* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

\* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan.

## 6. Sales Forecasts by Reporting Segment (FY 2014)

(billions of yen)

	FY 2013		FY 2014		
	Q3	Full year	Q3	Revised forecast	Previous forecast
<b>Japan</b>	240.7	311.0	213.3	<u>285.5</u>	307.5
<b>Prescription medicines</b>	219.1	281.6	189.5	<u>252.5</u>	274.0
Alzheimer's disease / Dementia with Lewy bodies treatment					
Aricept	52.3	65.0	37.0	<u>50.5</u>	59.5
Proton-pump inhibitor					
Pariet	36.9	47.3	28.8	<u>38.0</u>	42.0
Fully human anti-TNF- monoclonal antibody					
Humira	22.3	28.8	22.8	30.5	30.5
Peripheral neuropathy treatment					
Methycobal	19.6	25.2	17.2	23.0	23.0
Oral anticoagulant					
Warfarin	7.5	9.7	6.7	9.0	9.0
Anticancer agent					
Halaven	5.0	6.4	4.5	<u>6.0</u>	9.0
Osteoporosis treatment					
Actonel	6.0	7.7	5.2	7.0	7.0
Insomnia treatment					
Lunesta	2.0	2.9	3.4	<u>5.0</u>	6.5
Gastritis / Gastric ulcer treatment					
Selbex	5.3	6.7	3.7	<u>5.0</u>	6.0
<b>Generics (Elmed Eisai Co., Ltd.)</b>	17.1	23.4	19.4	<u>27.0</u>	27.5
<b>Diagnostics (EIDIA Co., Ltd.)</b>	4.4	6.0	4.4	6.0	6.0
<b>Americas</b>	106.8	158.9	87.5	<u>122.0</u>	111.5
<b>United States</b>	106.3	158.3	86.9	<u>121.0</u>	110.0
<b>China</b>	23.6	31.8	30.0	<u>41.0</u>	38.0
<b>Asia</b>	19.8	26.2	22.8	<u>31.0</u>	29.5
<b>EMEA</b>	23.8	32.0	28.5	40.0	40.0
<b>Consumer Healthcare Business - Japan (mainly OTC products)</b>	14.5	19.3	13.2	<u>17.5</u>	21.0
Vitamin B2 preparation, "Chocola BB Plus," etc.					
Chocola BB Group	9.2	12.0	8.3	<u>10.5</u>	12.5
<b>Other</b>	16.0	20.2	13.1	<u>18.0</u>	18.5
<b>Consolidated revenue</b>	<b>445.1</b>	<b>599.5</b>	<b>408.5</b>	<b><u>555.0</u></b>	<b>566.0</b>
<b>Global revenue from major products</b>					
Pariet/Aciphex	75.0	91.4	43.5	<u>57.0</u>	53.0
Aricept	66.4	82.7	49.4	<u>68.5</u>	75.5
Halaven	21.3	28.8	25.8	<u>36.5</u>	39.0
Japan	5.0	6.4	4.5	<u>6.0</u>	9.0
Americas	9.9	13.4	11.9	<u>16.5</u>	15.5
EMEA	6.1	8.5	8.4	<u>13.0</u>	13.5
Asia	0.3	0.5	0.8	1.0	1.0
Fycompa	1.0	2.1	2.6	<u>5.0</u>	9.5
Americas	0.0	0.8	0.9	<u>2.3</u>	7.0
EMEA	1.0	1.3	1.7	<u>2.7</u>	2.5

## 7. Consolidated Statement of Comprehensive Income

(billions of yen)

	FY 2013		FY 2014		
	Q3	Full year	Q3	YOY (%)	Diff.
Profit for the period	28.0	38.5	36.8	131.7	8.9
Other comprehensive income					
Items that will not be reclassified to profit or loss					
Financial assets measured at fair value through other comprehensive income	2.8	3.8	(0.2)		(3.0)
Remeasurements of defined benefit plans		2.5			
Subtotal	2.8	6.4	(0.2)		(3.0)
Items that may be reclassified subsequently to profit or loss					
Exchange differences on translation of foreign operations	48.3	38.8	66.7	138.2	18.4
Cash flow hedges	0.7	0.8	0.3	47.1	(0.4)
Subtotal	48.9	39.6	67.0	137.0	18.1
Total other comprehensive income, net of tax	51.7	46.0	66.8	129.2	15.1
Comprehensive income for the period	79.7	84.5	103.7	130.1	24.0
Attributable to					
Owners of the parent	79.5	84.3	103.5	130.1	24.0
Non-controlling interests	0.2	0.2	0.2	115.0	0.0

## 8. Consolidated Statement of Cash Flows

(billions of yen)

	FY 2013	FY 2014	
	Q3	Q3	Diff.
<b>Operating activities</b>			
Profit before income taxes	42.2	21.7	(20.5)
Depreciation and amortization	29.9	28.5	(1.4)
Impairment losses	0.3	0.0	(0.3)
(Increase) decrease in working capital	9.4	(2.2)	(11.6)
Interest and dividends received	1.5	1.4	(0.1)
Interest paid	(4.2)	(3.3)	0.8
Income taxes paid	(22.2)	(9.2)	12.9
Income taxes refund	0.2	3.9	3.7
Other	7.2	0.4	(6.8)
<b>Net cash from operating activities</b>	<b>64.4</b>	<b>41.2</b>	<b>(23.2)</b>
<b>Investing activities</b>			
Purchases of property, plant and equipment (1)	(6.3)	(9.5)	(3.2)
Proceeds from sale of property, plant and equipment (2)	2.8	2.2	(0.7)
Purchases of intangible assets (3)	(17.0)	(5.3)	11.7
<Capital expenditure (cash basis)> (1)+(2)+(3)	(20.5)	(12.6)	7.9
Purchases of financial assets	(3.9)	(6.5)	(2.6)
Proceeds from sale and redemption of financial assets	10.3	7.4	(2.8)
Payments of time deposits exceeding 3 months	(14.5)	(29.0)	(14.6)
Proceeds from redemption of time deposits exceeding 3 months	39.6	14.5	(25.1)
Proceeds from sale of investments in subsidiaries that result in a loss of control	0.9		(0.9)
Other	(0.1)	0.1	0.1
<b>Net cash from (used in) investing activities</b>	<b>11.8</b>	<b>(26.1)</b>	<b>(37.9)</b>
<b>Financing activities</b>			
Net increase (decrease) in short-term borrowings	7.6	21.0	13.4
Net increase (decrease) in commercial paper	10.0		(10.0)
Proceeds from long-term borrowings		106.9	106.9
Repayment of long-term borrowings	(19.9)	(117.7)	(97.9)
Redemption of bonds	(50.0)		50.0
Dividends paid	(42.8)	(42.8)	(0.0)
Other	(0.8)	(0.8)	0.1
<b>Net cash from (used in) financing activities</b>	<b>(95.9)</b>	<b>(33.4)</b>	<b>62.4</b>
Effect of exchange rate change on cash and cash equivalents	18.1	23.7	5.6
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(1.6)</b>	<b>5.3</b>	<b>6.8</b>
Cash and cash equivalents at beginning of period	142.5	153.9	11.5
Cash and cash equivalents at end of period	140.9	159.2	18.3
<b>Free cash flow</b>	<b>43.9</b>	<b>28.5</b>	<b>(15.3)</b>

\* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (cash basis)"

### Notes

#### Cash flow from operating activities:

Decrease in profit before taxes, etc.

#### Cash flow from investing activities:

In the corresponding period of the previous fiscal year, proceeds from redemption of time deposits exceeding 3 months were generated for redemption of corporate bonds

#### Cash flow from financing activities:

Repayments of long-term borrowings in the U.S.

Redemption of corporate bonds occurred in the corresponding period of the previous fiscal year

## 9. Consolidated Statement of Financial Position

### <Assets>

(billions of yen)

Assets

Non-current assets

Property, plant and equipment	134.1	13.8	135.1	12.9	100.8	1.0
-------------------------------	-------	------	-------	------	-------	-----

Goodwill

## <Equity and Liabilities >

(billions of yen)

### Equity

#### Equity attributable to owners of the parent

Share capital	45.0	4.6	45.0	4.3	100.0	
Capital surplus	57.9	6.0	58.0	5.5	100.0	0.0
Treasury shares	(38.5)	(4.0)	(38.0)	(3.6)	98.8	0.5
Retained earnings	379.2	38.9	372.9	35.5	98.3	(6.3)
Other components of equity	82.7	8.5	149.6	14.2	181.0	67.0
Total equity attributable to owners of the parent	526.3	54.0	587.5	55.9	111.6	61.1
Non-controlling interests	3.1	0.3	3.2	0.3	104.5	0.1
Total equity	529.4	54.4	590.7	56.2	111.6	61.3

### Liabilities

#### Non-current liabilities

Bonds and borrowings

## 10. Changes in Quarterly Results

### 1) Income Statement

	FY 2013				FY 2014		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Revenue	152.8	151.6	140.7	154.4	132.8	136.2	139.4
Cost of sales	46.2	47.1	54.2	47.2	48.1	45.7	49.3
Gross profit	106.6	104.5	86.5	107.2	84.7	90.5	90.1
Selling, general and administrative expenses	50.6	50.8	50.4	51.5	47.2	47.5	48.7
Selling expenses	21.8	23.1	15.4	18.6	16.8	18.6	15.6
Personnel expenses	18.4	17.7	18.8	19.3	19.3	18.4	20.4
Administrative and other expenses	10.4	10.0	16.2	13.6	11.0	10.5	12.7
Research and development expenses	37.3	30.5	35.7	32.9	29.1	33.0	35.8
Other income	0.3	3.4	0.1	0.2	0.2	0.4	0.1
Other expenses	0.4	0.3	0.3	1.7	0.1	0.9	(0.0)
Operating profit	18.6	26.3	0.2	21.3	8.5	9.6	5.8
Financial income	0.7	0.3	0.5	0.3	0.6	0.3	0.6
Financial costs							





## 5) Changes in Quarterly Revenue from Major Products

### (1) Oncology-Related Products

	FY 2013						
	Q1	Q2	Q3	Q4	Q1	Q2	Q3
<b>Total</b>	27.1	26.6	23.6	23.4	24.2	22.6	25.8
<b>Halaven (Anticancer agent)</b>	6.9	6.9	7.5	7.5	8.2	8.3	9.3
Japan	1.6	1.6	1.7	1.5	1.6	1.4	1.6
Americas	3.3	3.2	3.4	3.4	3.8	3.8	4.3
Asia	0.1	0.1	0.2	0.2	0.2	0.3	0.3
EMEA	2.0	1.9	2.2	2.4	2.6	2.8	3.1
<b>Aloxi (Antiemetic agent)</b>	10.3	11.1	10.8	10.7	12.6	11.0	12.6
<b>Treakisym/Symbenda (Anticancer agent)</b>	1.0	1.0	1.0	0.9	1.0	0.9	1.0
<b>Other</b>	8.8	7.6	4.3	4.3	2.5	2.4	2.9

# 11. Major R&D Pipeline

## In-House R&D Pipeline List

Product Name / Development Code	Additional Indication, etc.*	Development Stage**	Therapeutic Area
<b>New Approval</b>			
Halaven (Second-line treatment for breast cancer)	AI	(EU) approved	Oncology and Supportive Care
Aricept (Dementia with Lewy bodies)	AI	(JP) approved	Neurology
Pariet (Prevention of recurrence of gastric and duodenal ulcers during treatment with low-dosage aspirin, new 5 mg tablet)	AI, AF	(JP) approved	

## (1) Oncology and Supportive Care

Development Code: **E7389** Generic Name: **eribulin** Product Name: **Halaven**

Indications / Drug class: Anticancer agent / microtubule dynamics inhibitor

In-house

Description:

Development Code: **MORAb-004**

Indications / Drug class: Anticancer agent / humanized anti-endosialin monoclonal antibody			In-house
Description: A humanized IgG1 monoclonal antibody that targets Tumor Endothelial Marker 1 (TEM-1) / endosialin. Expected to show an antitumor effect against carcinomas that express endosialin.			
Melanoma	Study 201	US/EU: PII	Inj.
Colorectal cancer	202	US/EU: PII	Inj.
Sarcoma	203	US/EU: PII	Inj.

Development Code: **MORAb-009** Generic Name: **amatuximab**

Indications / Drug class: Anticancer agent / chimeric anti-mesothelin monoclonal antibody			In-house
Description: A chimeric IgG1 monoclonal antibody that blocks the function of mesothelin. Expected to show an antitumor effect against carcinomas that express mesothelin.			
Mesothelioma	Study 003	US/EU: PII	Inj.

Development Code: **E7820**

Indications / Drug class: Anticancer agent / alpha 2 integrin suppressant			In-house
Description: An angiogenesis inhibitor that suppresses the expression of alpha 2 integrin, a vascular endothelial cell adhesion molecule.			
Colorectal cancer	Study 702	US/EU: PII	Oral

Development Code: **E7272** Generic Name: **denileukin diftitox** Product Name: **Ontak**

Indications / Drug class: Anticancer agent / interleukin-2 diphtheria toxin fusion protein			In-house
Description: A fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxins. Selectively binds to IL-2 receptors on the cell surface, causing diphtheria toxins that have entered cells to inhibit protein synthesis. Already approved in the			

## (2) Neurology

Development Code: **E2020** Generic Name: **donepezil** Product Name: **Aricept**

Indications / Drug class: Anti-Alzheimer's agent		In-house	
Description: Increases levels of the neurotransmitter acetylcholine in the brain by inhibiting its breakdown by the enzyme acetylcholinesterase, thereby slowing the overall progression of symptoms associated with Alzheimer's disease (AD). Currently approved in more than 90 countries around the world for the treatment of mild to moderate AD. It is also approved as a treatment for patients with severe AD in numerous countries including the United States, Japan, Canada, and several other Asian and Latin American countries. Also approved in Japan for dementia with Lewy bodies in September 2014.			
Dementia with Lewy bodies (Additional Indication)	Study 341	JP: approved (September 2014)	Oral
Severe Alzheimer's disease (Additional Indication)	339	CN: PIII	Submission Target: FY2014 Oral

Development progress from April 2014 onwards      Development progress from October 2014 onwards

Development Code: **BAN2401**

Indications / Drug class: Anti-Alzheimer's agent / humanized anti-A $\beta$  protofibrils monoclonal antibody

In-license (BioArctic Neuroscience)

Development progress from April 2014 onwards      Development progress from October 2014 onwards

### (3) Vascular and Immunological Reaction

Generic Name: **flecainide** Product Name: **Tambocor**

Indications / Drug class: Anti-tachyarrhythmia agent	In-house
Description: Suppresses tachyarrhythmia by blocking cardiac sodium channels. The agent was approved for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter and ventricular tachycardia) in adults and tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia and ventricular tachycardia) in pediatric patients.	
Pediatric fine granule formulation (Additional Formulation)	JP: submitted (January 2014) Oral.

Development Code: **E5501/AKR-501** Generic Name: **avatrombopag**

Indications / Drug class: Treatment for thrombocytopenia / thrombopoietin receptor agonist	In-house
Description: A novel, oral thrombopoietin receptor agonist that stimulates platelet production. Expected to show effects against conditions that are associated with thrombocytopenia.	
Thrombocytopenia in chronic liver disease requiring surgery	Study 310/311 JP/US/EU/AS: PIII Submission Target: FY2015 Oral
Idiopathic thrombocytopenic purpura (ITP)	302 US/EU/AS: PIII Oral
Thrombocytopenia during interferon therapy (both initiation and maintenance) for hepatitis C	203 US: PII Oral

Japan was added to the global Phase III clinical study of thrombocytopenia in chronic liver disease requiring surgery.

Development Code: **E6005**

Indications / Drug class: Anti-atopic dermatitis / Phosphodiesterase 4 inhibitor	In-house
Description: Inhibits the activity of phosphodiesterase 4, a cyclic AMP-degrading enzyme that acts as an intracellular messenger. Expected to be effective as a treatment to suppress the various symptoms associated with atopic disease.	
Atopic dermatitis	Study 102 JP: PII Topical

Development Code: **E6011**

Autoimmune disorder/Inflammatory diseases (anti Fractalkine antibody)	PI/II	In-house	Inj.
---	-------	----------	------

Development Code: **MORAb-022**

Rheumatoid arthritis (antibody)	PI	In-house	Inj.
---------------------------------	----	----------	------

Development Code: **E6007**

Activated integrin inhibitors	PI	In-house	Oral.
-------------------------------	----	----------	-------

Development progress from April 2014 onwards      Development progress from October 2014 onwards



